Skip to main content

Table 1 Baseline characteristics of CHB-related compensated cirrhosis

From: Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study

  ADV-containing Non-ADV-containing p-value
(n=127) (n=115)
Age, (mean ± SD) 50 ± 12 50 ± 10 0.62
Gender    0.28
 Male 114 (89.8%) 98 (85.2%)  
 Female 13 (12.4%) 17 (9.7%)  
HBV DNA (log10 copy/mL, mean ± SD) 3.93 ± 1.31 3.88 ± 1.18 0.76
HBeAg    0.92
 Positive 92 (72.4%) 84 (73.0%)  
 Negative 35 (27.6%) 31 (27.0%)  
ALT (U/L, mean ± SD) 98.3 ± 23.6 96.3 ± 24.4 0.34
Total bilirubin (μmol/L), median (range) 16.1 (5.7-65.0) 14.4 (5.5-39.8) 0.11
ALB (g/L), median (range) 4.5 (3.8-6.3) 4.0 (2.9-6.1) 0.09
AFP, ng/mL, median (range) 4.91 (1.21-28) 5.41 (1.16-31) 0.08
PLT, 10^9/L, median (range) 186.31 (97-231) 178.44 (103-241) 0.13
Child-Pugh score    0.87
 A 122 (96.1%) 110 (95.6%)  
 B 5 (3.9%) 5 (4.4%)  
  1. HBeAg hepatitis B e antigen, AFP α-fetoprotein, ALB albumin, PLT platelet, SD standard deviation